Wednesday, June 7, 2023
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
Disclosures for additional planners can be found here.
Professor of Haematology
University of Birmingham
Birmingham, United Kingdom
Associate Professor of Infectious Diseases
University of Genova
Dipartimento di Scienze della Salute (DISSAL)
IRCCS Ospedale Policlinico San Martino
Genova, Italy
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
processing....
Posted: 02/10/2023
This activity is intended for an international audience of non-US infectious disease clinicians and hematology/oncology specialists.
The goal of this activity is that learners will have a better understanding of immunologic responses to and clinical evidence of COVID-19 vaccine effectiveness in immunocompromised patients as well as when to administer booster vaccinations.
Upon completion of this activity, participants will:
The goal of this activity is that learners will have a better understanding of immunologic responses to and clinical evidence of COVID-19 vaccine effectiveness in immunocompromised patients as well as when to administer booster vaccinations.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
